Sun Pharma recalls select eye drops, halts distributor sales as precaution
Sun Pharma has asked distributors to stop billing and return available inventory of select eye-drop products, including Depopred, Brinzotim, Lotepred and Nepalact OD. The company said it is working to restore supply, while advising patients to consult ophthalmologists for alternatives.
Sun Pharma has precautionarily recalled several eye-drop products, ordered distributors to stop billing and return available inventory, and said it is working to restore supply. Patients were advised to consult ophthalmologists for alternatives rather than independently stopping treatment.
Why this matters
The recall follows Sun Pharma's Q1 US generics sales decline of 9.7%, despite 16% growth in India formulations and Brazil approval for its semaglutide launch.
Retail-company signals are accelerating, up 222517% QoQ.